BioLine RX LtdNASDAQ:BLRXNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.7456
- TODAY'S CHANGE (%)-0.0742 (-9.0510%)
- Bid / Lots0.7700/ 1
- Ask / Lots0.8400/ 1
- Open / Previous Close0.8250 / 0.8198
- Day Range
- 52 Week Range
- Volume387,053
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | BLRX |
|---|---|---|
| 09:32 ET | 6553 | 0.81565 |
| 09:34 ET | 4500 | 0.81 |
| 09:36 ET | 3408 | 0.83 |
| 09:38 ET | 7552 | 0.83 |
| 09:39 ET | 210 | 0.8 |
| 09:41 ET | 1564 | 0.815 |
| 09:45 ET | 2000 | 0.8001 |
| 09:50 ET | 5280 | 0.8025 |
| 09:52 ET | 134 | 0.803 |
| 09:54 ET | 1399 | 0.79 |
| 09:56 ET | 3700 | 0.8 |
| 09:57 ET | 10800 | 0.796 |
| 09:59 ET | 607 | 0.8247 |
| 10:01 ET | 2060 | 0.8051 |
| 10:03 ET | 6040 | 0.79 |
| 10:06 ET | 1435 | 0.7928 |
| 10:08 ET | 400 | 0.7955 |
| 10:10 ET | 20665 | 0.7805 |
| 10:12 ET | 1128 | 0.7939 |
| 10:14 ET | 2250 | 0.78 |
| 10:15 ET | 1000 | 0.789999 |
| 10:17 ET | 13309 | 0.7601 |
| 10:19 ET | 100 | 0.79 |
| 10:21 ET | 2640 | 0.77 |
| 10:26 ET | 4147 | 0.7697 |
| 10:28 ET | 1400 | 0.7697 |
| 10:33 ET | 1000 | 0.764899 |
| 10:35 ET | 2153 | 0.76 |
| 10:39 ET | 9168 | 0.755 |
| 10:42 ET | 7027 | 0.7599 |
| 10:46 ET | 2300 | 0.7698 |
| 10:48 ET | 30900 | 0.7674 |
| 10:51 ET | 2620 | 0.79 |
| 10:55 ET | 162 | 0.788 |
| 11:00 ET | 3428 | 0.7766 |
| 11:09 ET | 1000 | 0.7879 |
| 11:13 ET | 206 | 0.773 |
| 11:15 ET | 2110 | 0.773 |
| 11:24 ET | 500 | 0.7797 |
| 11:26 ET | 1200 | 0.779799 |
| 11:27 ET | 4087 | 0.77 |
| 11:36 ET | 1250 | 0.77 |
| 11:45 ET | 1200 | 0.7798 |
| 11:47 ET | 5498 | 0.7651 |
| 12:02 ET | 500 | 0.7796 |
| 12:05 ET | 5245 | 0.7651 |
| 12:09 ET | 1644 | 0.7687 |
| 12:12 ET | 500 | 0.7653 |
| 12:16 ET | 224 | 0.7651 |
| 12:25 ET | 5882 | 0.7651 |
| 12:30 ET | 100 | 0.7675 |
| 12:32 ET | 1200 | 0.7675 |
| 12:38 ET | 250 | 0.7651 |
| 12:39 ET | 3200 | 0.7699 |
| 12:43 ET | 500 | 0.7699 |
| 12:45 ET | 6900 | 0.769 |
| 12:48 ET | 6900 | 0.78 |
| 12:56 ET | 1000 | 0.787199 |
| 12:57 ET | 500 | 0.7872 |
| 01:03 ET | 350 | 0.7872 |
| 01:08 ET | 500 | 0.787 |
| 01:17 ET | 5200 | 0.78 |
| 01:19 ET | 700 | 0.7801 |
| 01:24 ET | 600 | 0.7821 |
| 01:30 ET | 300 | 0.7801 |
| 01:33 ET | 3133 | 0.7707 |
| 01:39 ET | 1450 | 0.772525 |
| 01:46 ET | 322 | 0.7801 |
| 01:48 ET | 4500 | 0.77505 |
| 01:53 ET | 1880 | 0.77 |
| 02:00 ET | 2657 | 0.773978 |
| 02:02 ET | 20832 | 0.7605 |
| 02:06 ET | 4370 | 0.751 |
| 02:08 ET | 357 | 0.753 |
| 02:09 ET | 675 | 0.7561 |
| 02:15 ET | 2779 | 0.753 |
| 02:18 ET | 200 | 0.755 |
| 02:22 ET | 120 | 0.755 |
| 02:24 ET | 200 | 0.750101 |
| 02:33 ET | 3300 | 0.75148 |
| 02:36 ET | 2800 | 0.759 |
| 02:38 ET | 4131 | 0.7501 |
| 02:40 ET | 27190 | 0.75 |
| 02:44 ET | 2000 | 0.7568 |
| 02:45 ET | 400 | 0.752 |
| 02:58 ET | 4476 | 0.75 |
| 03:03 ET | 300 | 0.75 |
| 03:05 ET | 125 | 0.7534 |
| 03:07 ET | 11000 | 0.75 |
| 03:09 ET | 4900 | 0.75 |
| 03:16 ET | 750 | 0.7543 |
| 03:20 ET | 700 | 0.7544 |
| 03:23 ET | 1000 | 0.7528 |
| 03:25 ET | 900 | 0.7528 |
| 03:27 ET | 349 | 0.7553 |
| 03:30 ET | 2100 | 0.7554 |
| 03:36 ET | 28434 | 0.7401 |
| 03:48 ET | 250 | 0.7403 |
| 03:50 ET | 1000 | 0.7403 |
| 03:52 ET | 2400 | 0.7476 |
| 03:54 ET | 500 | 0.75 |
| 03:57 ET | 7900 | 0.7456 |
May 30, 2024
BioLineRx Announces Clinical Trial Agreement with St. Jude Children's Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell (HSC) Mobilization For Gene Therapy Applications in Sickle Cell Disease (SCD), from 7:00AM ET on Thursday May 30, 2024 by Dow Jones
7:00AM ET on Thursday May 30, 2024 by Dow Jones
May 29, 2024
DJ BioLine RX Price Target Maintained With a $21.00/Share by HC Wainwright & Co., from 10:34AM ET on Wednesday May 29, 2024 by Dow Jones
10:34AM ET on Wednesday May 29, 2024 by Dow Jones
May 28, 2024
BioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates, from 7:00AM ET on Tuesday May 28, 2024 by Dow Jones
7:00AM ET on Tuesday May 28, 2024 by Dow JonesPress Release: BioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates, from 7:00AM ET on Tuesday May 28, 2024 by Dow Jones
7:00AM ET on Tuesday May 28, 2024 by Dow Jones
May 24, 2024
BioLineRx Announces Abstract on Pilot Study Data from Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC) at American Society of Clinical Oncology (ASCO) 2024 Annual Meeting, from 7:00AM ET on Friday May 24, 2024 by Dow Jones
7:00AM ET on Friday May 24, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
BioLine RX Ltd | 58.4M | -1.0x | --- |
LAVA Therapeutics NV | 59.4M | -2.1x | --- |
Dyadic International Inc | 63.7M | -8.0x | --- |
Kronos Bio Inc | 47.5M | -0.4x | --- |
Kezar Life Sciences Inc | 50.5M | -0.5x | --- |
Cue Biopharma Inc | 79.3M | -1.5x | --- |
Company Information
BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.
Contact Information
- Headquarters
- Modi'in Technology Park 2 HaMa'ayan StreetMODIIN, Israel 7177871
- Phone
- ---
- Fax
- ---
Executives
- Chairman of the Board
- Aharon Schwartz
- Chief Executive Officer
- Philip Serlin
- Chief Financial Officer
- Mali Zeevi
- Vice President - Development
- Ella Sorani
- Vice President-Clinical & Medical Affairs
- Abi Vainstein-Haras
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $58.4M |
|---|---|
Revenue (TTM) | $11.7M |
Shares Outstanding | 79.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.54 |
EPS | $-0.76 |
Book Value | $0.18 |
P/E Ratio | -1.0x |
Price/Sales (TTM) | 5.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -391.76% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
